Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program | BMC Immunology | Full Text

Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program | BMC Immunology | Full Text

Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated ...

Authors:Javier Sánchez Ramírez, Yanelys Morera Díaz, Mónica Bequet-Romero, Francisco Hernández-Bernal, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Ana Victoria de la Torre Santos, Mariela Pérez de la Iglesia, Lian Trimiño Lorenzo and Marta Ayala Avila

Citation:BMC Immunology 2020 21:12

Content type:Research article

Published on: 14 March 2020

• ViewFull Text
 
• ViewPDF